Global Direct-to-Consumer Genetic Testing Market Size is valued at USD 2.4 Billion in 2024 and is predicted to reach USD 16.2 Billion by the year 2034 at a 21.2% CAGR during the forecast period for 2025-2034.
Direct access testing, also known as direct-to-consumer (DTC) testing, enables clients to order laboratory tests directly from a laboratory without necessarily involving their healthcare provider. Direct-to-consumer genetic testing provides a person's genetic information without needing a doctor or health insurance company. Customers can send the business a DNA sample and get immediate results. Direct-to-consumer genetic testing, among other things, raises awareness of numerous genetic illnesses that aid in predicting one's health and offer information on standard features and ancestry. DTC genetic testing is quick to deliver findings confidently, inexpensively, and easy to use. Such scenarios will help the market expand beneficially.
One of the main factors projected to fuel the growth of the direct-to-consumer (DTC) genetic testing market over the anticipated period is the rise in public awareness. The direct-to-consumer (DTC) genetic testing industry is also expected to grow due to the increase in income levels in developing nations. Additionally, the growing need for service personalization will likely create additional chances for the direct-to-consumer (DTC) genetic testing industry to expand over the next few years.
However, direct-to-consumer (DTC) genetic testing market expansion may be hindered in the near future by flaws in the DTC testing kits. Direct-to-consumer (DTC) genetic testing market expansion is anticipated to be hampered over the timeframe due to the rising cost of DTC genetic testing. Furthermore, insufficient data links a particular genetic mutation to a given illness or functionality. Genetic privacy may also be jeopardized if testing businesses utilize their clients' genetic data improperly or if the information is stolen.
Market Segmentation:
The Direct-to-Consumer Genetic Testing Market is segmented based on type, type of technology, and distribution channel. Based on type, the market is segmented into nutrigenomics testing, predictive testing, carrier testing, and others. Based on the type of technology, the market is divided into whole genome sequencing, single-nucleotide polymorphism chips, targeted analysis, and others. Based on the distribution channel, the market is divided into online platforms, OTC.
The Predictive Testing Segment is Expected to Have the Highest Growth Rate During the Forecast Period
Based on type, the market is segmented into nutrigenomics testing, predictive testing, carrier testing, and others Among these, the predictive testing segment is expected to have the highest growth rate during the forecast period. his segment is also expected to experience the fastest growth over the forecast period. The popularity of predictive testing is driven by consumers' increasing interest in understanding their genetic predispositions to various health conditions, enabling proactive health management. Predictive genetic tests offer valuable information on potential health risks, giving consumers a sense of control over their health and the ability to make informed decisions. Tests that assess genetic risks for common diseases like breast cancer (or cardiovascular disease are particularly popular.
The Whole Genome Sequencing (WGS) Segment Dominates the Market
Based on the type of technology, the market is divided into whole genome sequencing, single-nucleotide polymorphism chips, targeted analysis, and others. The whole genome sequencing (WGS) segment dominates the market. Advancements in sequencing technologies and a reduction in the cost of genome sequencing have made WGS more affordable and accessible to consumers. The initial high cost of whole genome sequencing has decreased significantly, making it a viable option for direct-to-consumer testing. WGS offers high accuracy and reliability in identifying genetic variations across the entire genome. This comprehensive data allows for a more precise understanding of an individual's genetic predispositions and potential health risks.
The North American Direct-To-Consumer Genetic Testing Market Holds A Significant Revenue Share In The Region.
In the forecast period, North America to hold a major global market share. The high prevalence of rare illnesses, the presence of numerous disease registries, a sizable number of R&D centres for ultra-rare diseases, and significant investments in disease detection are all factors that contribute to the region's considerable market share. Customers with a lot of disposable money can spend more on direct-to-consumer genetic testing, like genetic and nutrigenomics testing, which encourages regional growth. In addition, the arrival of significant industry players in the area and accelerated technology advancements will foster market expansion locally.
During the forecasted years, Asia Pacific is anticipated to experience significant growth. This is primarily due to improvements in awareness and diagnostic skills. Furthermore, this region will benefit financially from implementing frameworks and policies that support illness management. In China, only a relatively smaller percentage of the population uses genetic screening services, although demand is augmenting. With this, many foreign businesses are anticipated to enter the China direct-to-consumer genetic testing industry to offer affordable services.
Recent Developments:
- In Feb 2025, Myriad Genetics, Inc, announced that the United States Patent and Trademark Office has issued two new patents that further advance Myriad’s ability to bring its tumor-informed, high-definition, molecular residual disease (MRD) assay to market.Myriad’s Precise MRD test is a whole-genome sequencing (WGS)-based assay, enabling the custom selection of hundreds to thousands of targeted variants for deep analysis. Myriad’s MRD assay targets 1,000 sites specific to the tumor genome, enabling sensitive detection of very low tumor levels.
- In Jan 2022, 23andMe Holding Co obtained FDA approval for a genetic health risk assessment of a marker for hereditary prostate cancer. After the FDA previously authorized 23andMe's BRCA1/BRCA2 (Selected Variants) Genetic Health Risk report and cleared it for MUTYH-Associated Polyposis (MAP), a hereditary colorectal cancer syndrome, this is the company's third cancer risk report clearance.
Competitive Landscape
Some Major Key Players In The Direct-To-Consumer Genetic Testing Market:
- 23andme Inc.,
- 24Genetics,
- Atlas Biomed,
- Color Genomics,
- DNAfit,
- Gene by Gene,
- Chengdu Twenty-Three Rubik’s Cube Biotechnology Co., Ltd.,
- EasyDNA,
- Mapmygenome,
- MyHeritage Ltd.,
- Laboratory Corporation of America Holdings,
- Myriad Genetics, Inc.,
- Konica Minolta, Inc.,
- XCODE Life.
Direct-to-Consumer Genetic Testing Market Report Scope :
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 2.4 Billion |
|
Revenue Forecast In 2034 |
USD 16.2 Billion |
|
Growth Rate CAGR |
CAGR of 21.2% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn,and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Type, Type of Technology, Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia; |
|
Competitive Landscape |
23andme Inc., 24Genetics, Ancestry.com LLC, Atlas Biomed, Color Genomics, DNAfit, Gene by Gene, Chengdu Twenty-Three Rubik’s Cube Biotechnology Co., Ltd., EasyDNA, Mapmygenome, MyHeritage Ltd., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Konica Minolta, Inc., XCODE Life. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
